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Abstract: Several rare neurodegenerative diseases, including chorea acanthocytosis, are caused by
mutations in the VPS13A–D genes. Only symptomatic treatments for these diseases are available.
Saccharomyces cerevisiae contains a unique VPS13 gene and the yeast vps13∆mutant has been proven as
a suitable model for drug tests. A library of drugs and an in-house library of natural compounds and
their derivatives were screened for molecules preventing the growth defect of vps13∆ cells on medium
with sodium dodecyl sulfate (SDS). Seven polyphenols, including the iron-binding flavone luteolin,
were identified. The structure–activity relationship and molecular mechanisms underlying the action
of luteolin were characterized. The FET4 gene, which encodes an iron transporter, was found to be
a multicopy suppressor of vps13∆, pointing out the importance of iron in response to SDS stress.
The growth defect of vps13∆ in SDS-supplemented medium was also alleviated by the addition of
iron salts. Suppression did not involve cell antioxidant responses, as chemical antioxidants were not
active. Our findings support that luteolin and iron may target the same cellular process, possibly the
synthesis of sphingolipids. Unveiling the mechanisms of action of chemical and genetic suppressors
of vps13∆ may help to better understand VPS13A–D-dependent pathogenesis and to develop novel
therapeutic strategies.
Keywords: yeast model; neurodegenerative diseases; VPS13 genes; drug repurposing; luteolin;
tolcapone; FET4 gene; iron; sphingolipid biosynthesis; csg2∆
1. Introduction
Neurodegenerative diseases (NDs) are a group of age-related diseases characterized by progressive
neuronal loss, which manifest in a decline of motor or cognitive function. The most common NDs
are Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). In these
diseases, one can observe the presence of protein aggregates which contain amyloid β, α-synuclein,
and huntingtin, respectively [1], as well as defects in various cellular processes [2–4]. These diseases are
among the most investigated NDs. However, some NDs are very rare and attract much less attention.
Such an ND is chorea-acanthocytosis (ChAc), with about 1000 cases estimated worldwide [5]. ChAc is
caused by mutations in VPS13A gene [6,7], one of the four VPS13 homologs present in the human
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genome [8]; about 90% of these cause a lack of the VPS13A (or chorein) protein [9]. Mutations in
other VPS13 (B–D) genes have also been linked to different diseases with neurological defects [10–14].
Currently, there is no cure for VPS13-associated diseases, only symptomatic treatment is offered.
The state of knowledge about these diseases is relatively low and their pathological mechanisms remain
unknown [15,16].
To investigate NDs and to find effective therapies, studies on model organisms, such as the yeast
Saccharomyces cerevisiae, have been carried out [17]. Yeasts enable research approaches unavailable in
higher eukaryotes, such as large-scale genetic screening or functional genomics [18]. Yeast models
of most NDs express a pathological variant or overexpress a gene associated with a disease [17,19].
Such models can be effectively used to better understand the diseases, identify molecular targets
suitable for drug treatment, and select protective molecules [20]. Some of these molecules have been
shown to be active in cell culture models and patient-derived cells [21–25]. A study using a PD yeast
model identified flavonoids as an active group of compounds against α-synuclein toxicity [23].
Flavonoids are a diverse group of chemical compounds found in plants. The core of flavonoids
consists of two benzene rings linked by a heterocyclic pyranic ring. Their diversity results from
numerous combinations of types, number, and locations of functional groups bound to the core, which
influences their biological activity [26,27]. Flavonoids exhibit antioxidant, antiviral, antibacterial,
anti-inflammatory, and anticancer activities [26–30]. Some flavonoids have also shown neuroprotective
properties in models of AD and PD, thus being promising drugs for use in clinical trials of NDs [31,32].
The biological effects of flavonoids result from different mechanisms of action, such as the modulation
of signaling pathways, antioxidant systems, and metal chelation actions, including iron [27,33].
Iron is necessary for many vital metabolic processes and is the substrate of ROS-generating Fenton
reactions. It is an essential cofactor of hemeproteins and Fe-S cluster-containing enzymes, which take
part in various cellular processes such as respiration and lipid biosynthesis [34]. Iron homeostasis in
yeast is regulated by the transcription factors Aft1 and Yap5, which respond to low and excessive iron
availability, respectively [35,36]. Aft1 induces the transcription of genes encoding the components of
iron uptake and regulating intracellular iron transport and storage [37]. Depending on iron availability,
different iron uptake systems are used by cells. In iron-depleted conditions, yeast cells rely on
high-affinity iron uptake systems consisting of Fet3 oxidase and Ftr1 permease. If iron is abundant,
uptake is mediated by the low-affinity and low-specificity Fet4 transporter [38–40]. Another mechanism
of iron uptake is the import of iron-siderophore chelates by siderophore transporters belonging to the
Arn/Sit family of proteins [37].
As S. cerevisiae contains a homolog of the disease-associated VPS13A–D genes, disease models can
be created by its deletion or by introducing mutations corresponding to the ones found in patients.
These approaches have been used for modelling and studying diseases associated with VPS13 genes
in previous studies [41–43]. The yeast mutant devoid of the VPS13 gene (vps13∆), as well as the
vps13-I2749R strain—carrying a mutation in VPS13 corresponding to one found in a ChAc patient—were
viable but showed defects in protein trafficking [9]. We have recently found that both vps13 mutant
cells are hypersensitive to very low amounts of the detergent sodium dodecyl sulphate (SDS) [43].
We used this phenotype to screen for multicopy suppressor genes and identified the fragment of the
MYO3 gene encoding type I myosin and other genes. The growth defect of the vps13∆ deletion mutant
can also be suppressed by FK506, which inhibits calcineurin, a calcium-dependent phosphatase [43].
Therefore, the vps13∆ strain can be used as a simple model for VPS13-associated diseases, whereas the
chemical suppression of vps13∆ growth defects can be explored as a tool for drug screening.
In this study, we searched for compounds restoring the vps13∆ growth defect in the presence of
SDS. The Prestwick library of FDA-approved drugs and an in-house library of natural compounds and
their derivatives were screened, leading to the identification of tolcapone and flavonoids, including
luteolin, as active chemical suppressors of vps13∆ growth defects. Furthermore, these studies allowed
for the identification of the structural determinants of their activity. We also found FET4 to be a
multicopy suppressor of vps13∆. Functional and genetic interactions of luteolin, iron compounds,
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and mutations affecting iron homeostasis and sphingolipid synthesis were also investigated, in order
to unveil the possible mechanisms of action of these compounds.
2. Materials and Methods
2.1. Strains, Media, and Growth Conditions
The E. coli strain DH5α was used for plasmid propagation. The S. cerevisiae strains used in this
study are listed in Table S1. YPD complete medium (1% yeast extract, 2% tryptone, 2% glucose,
1% adenine) or synthetic SC medium (0.067% yeast nitrogen base without amino acids, 2% glucose)
with desired supplements (adenine, uracil, amino acids) were used for yeast cultivation. Growth
experiments on media with SDS addition were performed using several dilutions of SDS stock solution
and images were taken after different time durations, in order to show the most representative and
informative results. This experimental approach was necessary, due to the high sensitivity of mutant
cells to small changes of final SDS concentration in the plate, which strongly depends on the lot
of medium and SDS stock, as well as various physical factors [43]. Plates were incubated at 28 ◦C.
For drop tests, cells were grown overnight in liquid media and cultures were diluted in sterile distilled
water to obtain a cell density equal to OD600∼1 or OD600∼0.1. Subsequently, aliquots of 4-fold serial
dilutions of cultures were spotted onto solid media. Chemical compounds added to the YPD medium
can be found in Table S2.
KJK181A vps13∆, KJK182 csg2∆ vps13∆, and KJK183 ipt1∆ vps13∆ strains were constructed by
deletion of VPS13 using the vps13::URA3 cassette. To this end, the strains BY4741, BYcsg2∆, and BYipt1∆
were transformed with PCR products obtained using pKA475 plasmid (Table S3) as a template and
transformants were selected on SC medium without uracil (SC-ura). Genomic integrations were
confirmed by PCR on genomic DNA. These strains were used to test SDS sensitivity phenotype and
the effect of luteolin and iron salts on cellular growth.
2.2. Plasmids
Plasmids used are listed in Table S3. Plasmid pFL44-FET4, bearing a genomic DNA fragment
with FET4 gene, was isolated as a multicopy suppressor of vps13-I2749R SDS hypersensitivity
phenotype [43] from the pFL-44 genomic bank [44]. The FET4 gene was amplified by PCR and
transferred to YEplac181 [45] and pRS425-PGPD [46] plasmids to obtain YEp181-FET4 and pRS425-PGPD-
FET4, respectively.
2.3. Drug Screening Assay
The assay was based on previously described tests [47,48]. Briefly, vps13∆ cells were grown
to early exponential phase, OD600 was adjusted to 0.5, and 200 µL was spread homogenously onto
solid YPD media supplemented with 0.03% SDS (12 × 12 cm square Petri dishes). Sterile filters were
placed on the media surface and 2 µL of 10 mM drug solution in dimethyl sulfoxide (DMSO) were
applied to each filter disc. In this screen, all 1280 compounds from the Prestwick Chemical Library
(Prestwick Chemical, Illkirch-Graffenstaden, France; last used April 2017), the majority of which have
been approved by Food and Drug Administration, USA, were tested. DMSO was used as a vehicle
control. The plates were incubated at 28 ◦C for 3 to 5 days. Data were recorded using a Snap Scan1212
(Agfa, Mortsel, Belgium).
2.4. Screen of an In-House Library of Natural Compounds and Their Derivatives
The in-house library of natural compounds and their derivatives (Table S2 [49]) was composed
from 5 µg/µL stocks in DMSO. An over-night pre-inoculum of vps13∆ strain was refreshed and
incubated in the shaker at 28 ◦C for 5 h. Samples corresponding to OD600 0.2 were taken, diluted
to a final volume of 250 µL, and spread onto YPD for control and YPD 0.03% SDS medium plates
(14 cm round or 12 × 12 cm square). Compounds from the library were applied on filter discs (10, 20,
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and 30 µg per spot). Mock-treated cells (DMSO solvent only) served as negative control, and luteolin
(identified in a drug screen of Prestwick library, described above) as positive control. The plates were
incubated at 28 ◦C for 3 to 5 days. Structure–activity relationship (SAR) analysis was carried out by
testing sets of compounds of various structures (Table S2). For SAR, 30 mg of compounds were spotted
on filter discs put on YPD, YPD + SDS 0.025%, and YPD + SDS 0.03% solid media with plated vps13∆
strain and observed after 3 to 7 days.
3. Results
3.1. Drug Library Screening Assay Using vps13∆ Strain and SDS Hypersensitivity Phenotype Revealed
Luteolin and Tolcapone as Active Compounds
We have previously described that the yeast vps13∆ mutant exhibits SDS hypersensitivity and
showed that this phenotype has the potential for drug screening [43]. In this study, we adapted this
phenotype for drug screening assays (Figure 1) [48], in order to identify molecules preventing the
lethality caused by VPS13 deletion. As SDS is inherently toxic, compounds reducing its toxic properties
could also be identified and, thus, the other phenotype—cadmium sensitivity—was subsequently tested
(see below). We screened the Prestwick drug repurposing library (Prestwick Chemical) previously
used in such screens [48,50], which contains drugs accepted for use in humans. Active compounds
were identified after 3–5 days by the observation of growth zones around the filter. Their activity was
then confirmed in independent experiments. Seven drugs were identified as suppressors of vps13∆
growth defect and two showing some structural similarities were selected for further analysis: luteolin,
a naturally occurring flavonoid present in many fruits and vegetables, and tolcapone, a drug used to treat
PD, which is a reversible nitrocatechol-type inhibitor of catechol-O-methyltransferase [51] (Figure 1).
Another flavonoid present in the Prestwick library, ipriflavone, was not active (Figure 1). To elucidate
the structural determinants important for activity, we performed further analyses (see below).
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Figure 1. Luteolin and tolcapone are chemical suppressors of vps13∆ growth defect. The vps13∆ cells
were plat d on YPD + SDS 0.03%. Compounds from the Prestwick library were applied on filter discs
(2 µL of 10 mM solution in DMSO). DMSO was used as a negative control. Plates were incubated for
3 days.
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3.2. Screen of an In-House Library of Natural Compounds and Their Derivatives Revealed Six Compounds from
Two Structural Classes, Flavonoids, and Tannins
Identification of luteolin as a suppressor of vps13∆ growth defect prompted us to screen an
in-house library of natural compounds and their derivatives, in order to evaluate further the efficacy of
these compounds as chemical suppressors of vps13∆ growth defect in the presence of SDS. Of about
fifty compounds tested (Table S2), five—namely, quercetin, pentaacetylquercetin, myricetin, fisetin, and
corilagin—were shown to restore vps13∆ growth on SDS plates (Figure 2). Among all positive-acting
drugs, luteolin caused the largest growth zone (Figure S1). Quercetin, myricetin, and fisetin belong to
the group of flavonoids with hydroxyl groups positioned in different carbons of the 3-hydroxyflavone
backbone. Pentaacetylquercetin can be deacetylated to quercetin and the activity we observed may
have been derived from this active metabolite. Corilagin is a member of the group of hydrolysable
tannins, which have a complex structure. Kaempferol, which also belongs to the group of flavonoids,
was not active (Figure 2). The identified flavonoids were also active as chemical suppressors of
cadmium hypersensitivity of vps13∆ cells; furthermore, they also improved the growth of the wild-type
strain (Figure S2). Thus, we further focused on SAR analysis of flavonoids.
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Figure 2. Flavonoids and tannins are chemical suppressors of vps13∆ growth defect. The vps13∆
strain was plated on YPD + SDS 0.03%. Luteolin was used as a positive control and DMSO as the
vehicle control. Kaempferol is indicated as an example of a non-active flavonoid in the conditions used.
Compounds were applied at 30 µg per spot. Plates were incubated for 5 days. Two quercetin samples
from separate stocks were used.
3.3. Analysis of the Structural Determinants of Flavonoids Activity as vps13∆ Suppressors
To find determinants of flavonoid structure responsible for the vps13∆ chemical suppressor
activity, we first tested a set of flavonoids varying in the number and position of hydroxyl groups, such
as 3′,5′-dihydroxyflavone, 3′,4′-dihydroxyflavone, 3′,4′,7-trihydroxyflavone, 3′,4′,7,8-tetrahydroxy
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flavone, butein, scutellarein (4′,5,6,7-tetrahydroxyflavone), and 7,8-dihydroxyflavone. The SAR
analysis revealed that two is the minimal number of hydroxyl groups and they must be located on
adjacent carbons of the B (preferred) or A ring (Figure 3). In addition to the flavones and flovonols,
butein (2′,3,4,4′-tetrahydroxychalcone), an intermediate in the biosynthesis of some flavonoids, was also
tested. Although butein does not possess a heterocycle (the corresponding part of the C ring is open),
the hydroxyl group positions 3 and 4 are equivalent to positions 3′ and 4′ in flavones. Interestingly,
butein was also active (Figure 3), indicating that it is not important whether the C ring is closed or
opened, unless other rules are met. These conclusions are also supported by the identification of
tolcapone from Prestwick library, which contains A and B rings, but has an open C ring and contains
two hydroxyl groups on adjacent carbons (see Figure 1).
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Figure 3. The vps13∆ growth-restoring activities of various flavonoids. The vps13∆ strain was plated
on YPD + SDS 0.03% and YPD for control. The structure of compounds, belonging to different
structural subclasses, are shown. Luteolin was used as positive control, and DMSO as negative control.
Compounds were applied at 30 µg per spot, according to the diagram. Plates were incubated for 1 or
3 days.
Then, we asked if other structural elements are important for the activity and tested a second
set of flavonoids. This set included luteolin, fisetin, and myricetin, which served as positive controls
(see Figure 2); hyperoside (quercetin 3-d-galactoside), which is glycosylated flavonol; taxifolin,
cyaniding, catechin and epicatechin, which have various structures with three rings; and flavone
as negative control (Figure 4). The analysis showed that the introduction of a glycoside abolished
the activity of quercetin. Moreover, the presence of a carbonyl group in the C ring and a double
bond between C2 and C3 atoms, in addition to at least two hydroxyl groups in the A or B ring, are
also required for activity. These structural features are similar to those previously associated with
the antioxidant and metal chelation properties of flavonoids [52–54]. However, several antioxidant
molecules, including trolox (present in Prestwick library), kaempferol (Figure 2), and catechin (Figure 4),
the latter having higher antioxidant potential than luteolin [54], were not active. Thus, the iron chelating
property, not antioxidant activity, is possibly important for vps13∆ suppression by flavonoids.
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3.4. The FET4 Gene E coding Iron Transporter Fet4 Sup resse ∆ and Mutations Affecting Iron
Transpo t Result in SDS Hypersensitiv ty
In a multicopy genomic library screen for sup ress r enes of vps13 SDS hypersensitivity
phenotype [43], we identified a plasmid containing the FET4 gene encoding a low affinity plasma
membrane iron (Fe2+) transporter [38] (Figure 5a). This finding indicated the importance of iron
transport in the response to SDS stress. However, placing the FET4 gene under the control of a strong
constitutive promoter, GPD, caused less efficient suppression, suggesting that FET4 expression must
be tightly controlled by the native promoter (Figure 5a). Addition of luteolin to SDS plates improved
vps13∆ growth, irrespective of the presence of FET4. There seemed to be no cumulative effect of
exposing cells to luteolin and overexpression of FET4, consistent with the vie that both tr atments
may act on the same pathway. The parental wild-type strain also displayed growth nhancement
in response to lute lin, which mitigates SDS toxicity even in the presence of Vps13, but t e effect
on vps13∆ was more pronounced in test conditions. These findings are in line with the view that a
moderate increase of iron in vps13∆ cells may help to cope with SDS stress.
Further corroboration of the functional association between iron transport and vps13∆ growth
restoration on SDS-containing plates was provided by the analysis of a set of deletion mutants, devoid
of genes encoding iron transporters fet3∆ and fet4∆; siderophore transporters arn1∆, arn2∆, sit1∆,
and enb1∆; or transport factors fre1∆ and fre2∆. Interestingly, fet3∆, fet4∆, arn1∆, arn2∆, fre2∆, and
enb1∆ mutants appeared to be more sensitive to SDS, as compared to the wild-type strain (Figure 5b),
supporting the notion that SDS stress response requires controlled upregulation of iron uptake which
apparently does not involve Sit1 siderophore transporter or ferric reductase Fre1, which reduces
siderophore-bound iron. Interestingly, the growth of wild-type and these mutant strains was improved
by addition of luteolin (Figure 5b). Iron is easily bound by flavonoids [53,55]; thus, luteolin may
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(directly or indirectly) act by supporting iron transport into the cell, or may affect the same processes
for which additional iron is required. Possibly, the impairment of iron transport in response to SDS
stress may be the cause of hypersensitivity of vps13∆, which is corrected either by FET4 upregulation
or by luteolin.
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Figure 5. Genetic link between iron transport, luteolin, and SDS hypersensitivity. (a) The vps13∆
growth defect on SDS media is suppressed by FET4 overexpression and by luteolin. Growth of vps13∆
strain bearing a plasmid expressing FET4 from native or GPD promoter, or empty vector, was compared
with respective controls by drop test on YPD, YPD + SDS 0.025%, and YPD + SDS 0.025% + luteolin
25 µM plates. Images were taken after 2 or 3 days of incubation. (b) Mutants defective in iron transport
are hypersensitive to SDS; this phenotype is suppressed by luteolin. Growth of fet3∆, fet4∆, arn1∆,
arn2∆, sit1∆, fre1∆, fre2∆, and enb1∆ strains on YPD, YPD + SDS 0.03%, and YPD + SDS 0.03%+luteolin
25 µM plates was compared with ild-ty e and vps13∆ controls by drop test. Images were taken after
2 or 4 days of incubation.
3.5. Iron Salts and Enterobactin Are Chemical Suppressors of vps13∆
To explore the g netic li k between iron transport, luteolin, and SDS sensitivity, we test d various
iron comp nds for their effect n vps13∆ gr wth on SDS-containing plates. Addition of soluble iron
salts, namely iron(II)chloride, iron(III)chloride, and iron ammonium sulfate (Mohr’s salt) restored
growth of vps13∆ cells on SDS plates (Figure 6a). A small zone of inhibition close to the filter was
observed, indicating that high iron ion concentrations were toxic. These results may indicate that vps13∆
cells require an excess of iron to respond to SDS stress or that they have an iron deficit. An argument
against the last possibility is the fact that the transcriptional activation of FET3 and CTH2, which
are involved in a signaling pathway responding to iron deficiency [56], was unchanged in vps13∆,
compared to the wild-type and upon SDS stress, as tested using the respective lacZ reporter fusions
(Figure S3a,b). Moreover, the sensitivity of vps13∆ to ferrozine, a strong iron chelator, was similar to
that of the wild-type strain (Figure S3c), suggesting that iron levels were similar in both strains.
We also tested whether the growth phenotype of vps13∆ was affected by enterobactin (also known
as enterochelin; Figure 6b), which is a high affinity siderophore belonging to the catechol group of
compounds. It is found in bacteria such as Escherichia coli and Salmonella typhimurium. Enterobactin
bound to Fe3+ is transported by the Enb1 transporter into yeast cells [57]. Interestingly, enterobactin
restored growth of vps13∆ on SDS-containing plates (Figure 6c). Enterobactin also contains structural
elements, such as two hydroxyl groups on adjacent carbons of the benzene ring and a carbonyl group
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in the central ring (Figure 6b), which we found important for vps13∆ SDS phenotype suppression by
flavonoids in the SAR analysis. This suggests that enterobactin and flavonoids, such as luteolin and
fisetin, may suppress the growth phenotype of vps13∆ by a similar iron-dependent mechanism.
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Figure 6. Iron salts and enterobactin restore growth of vps13∆ cells on SDS plates. (a) The vps13∆
strain was plated on YPD + SDS 0.03%. Iron salts (FeCl3, FeCl2, and Mohr’s salt Fe(NH4)2(SO4)2)
were applied at 10 µL of 1 M solution per spot. Plates were incubated for 5 days. (b) Structure of
enterobactin. (c) The vps13∆ strain was plated on YPD + SDS 0.03%. Enterobactin and flavonoids were
applied at 10 µg per spot. Luteolin and fisetin were used as positive controls, and DMSO as negative
control. Plates were incubated for 5 days.
3.6. Characterization of the Possible Mechanism of Flavonoids Action
The importance of iron supply in the response of vps13∆ cells to SDS turned our attention to
iron-dependent cellular processes, hich might be essential under this stress condition. Iron ions
are cof t r f e proteins, Fe-S clusters proteins, and other enzymes, which take part in several
processes, including ron t a sport and lipi biosynthesis [34]. Lipid b osynthetic pa hways, producing
unsaturated fatty cids, sterols, and sphingolipids, contain heme proteins. Thus, iron co-ordinates the
synthesis of various lipids in response to cell needs. SDS, as a detergent, disrupts the cell wall and
plasma membrane; thus, the remodeling of the cell wall and lipid composition of the plasma membrane
are crucial in the SDS response [43,58,59]. Sphingolipid biosynthesis has previously been found
to be important for SDS tolerance. Cells devoid of IPT1, encoding inositolphosphotransferase
responsible for the last step in the biosynthesis of the major plasma membrane sphingolipid
mannose-(inositol-P)2-ceramide [M(IP)2C] [60], and CSH1 and SUR1, encoding mannosylinositol
phosphorylceramide (MIPC) synthase catalytic sub-units [61,62], have been shown to be hypersensitive
to SDS [58]. Thus, the sensitivity of csg2∆ and ipt1∆ mutants, defective in complex sphingolipid
biosynthesis, to various SDS concentrations, and their genetic interaction with vps13∆ mutation in
these conditions were tested. The csg2∆ strain, devoid of a protein required for the mannosylation
of inositolphosphorylceramide (IPC), was more sensitive than ipt1∆ to SDS, as csg2∆ grew slower
while ipt1∆ grew at a similar rate to the wild-type strain on YPD + SDS 0.015% (Figure 7). The effect
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of both these mutations was additive with vps13∆, as csg2∆ vps13∆ did not grow on YPD + SDS
0.015% and ipt1∆ vps13∆ stopped growing when the SDS concentration was higher (YPD + SDS 0.02%;
Figure 7) while respective single mutants grow in these conditions. These negative genetic interactions
suggest that Vps13 contributes to cell survival during SDS stress in parallel to complex sphingolipid
biosynthesis pathways. Interestingly, when suppression by luteolin or FeCl2 of the respective mutants
was studied, it was observed that csg2∆, ipt1∆, and the respective double mutants csg2∆ vps13∆ and
ipt1∆ vps13∆ were suppressed (Figure 7). Thus, MIPC and M(IP)2C, the last two products of the
sphingolipid biosynthesis pathway, seemed not to be important in the action of luteolin and FeCl2 on
vps13∆ cells. As vps13∆ and csg2∆ or ipt1∆ showed genetic negative interaction and luteolin or iron
suppressed growth defect of single and double mutants, we conclude that there must be a pathway,
independent of the Vps13 protein and the synthesis of complex sphingolipids or the upregulation or
downregulation of which, by the administration of luteolin or iron, is helpful under SDS stress.
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suppressed by luteolin and iron salt, and negati l interact with vps13∆. Gro th of wild-type,
vps13∆ (KJK181A), csg2∆, ipt1∆, and the respective double utants on YPD plates containing SDS was
compared by drop test. The effect of luteolin and FeCl2 on growth is also shown. Images were taken
after 2 or 3 days of incubation.
4. Discussion
The pathogenesis of neurodegenerative diseases caused by mutations in VPS13A-D genes is
not well understood and no effective treatment is available. Simple model organisms, such as the
yeast S. cerevisiae, offers opportunities to improve our understanding of cellular pathogenic processes
and perform drug repurposing screening. This is possible by using mutations in the yeast VPS13
gene encoding the Vps13 protein, the orthologue of human VPS13A-D gene products [9]. In this
paper, we screened the Prestwick library and an in-house library of natural compounds and their
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derivatives and identified several polyphenols, including the flavone luteolin, for protective compounds
overcoming some of the defects caused by Vps13 deficiency. These defects can also be reversed by
overexpression of FET4, encoding an iron transporter, and the addition of iron salts or iron-binding
siderophores to the medium. This indicates the importance of cellular iron concentration for vps13∆
cells to survive under stress and provides a link to the metabolic pathway, which we conclude to be
involved in the mechanism of luteolin action—the sphingolipid biosynthesis pathway.
Screening of the Prestwick drug repurposing library and an in-house library of natural compounds
and their derivatives revealed several polyphenols from the group of flavonoids and tannins as able to
overcome the defects caused by Vps13 deficiency. Besides the SDS hypersensitivity phenotype used
in the screen, the cadmium hypersensitivity of vps13 cells was also effectively suppressed, showing
that the mechanism of action of the selected compounds was not SDS-specific but more general.
However, some transport defects, such as the defect of Sna3-GFP transport to the vacuole [42] were
not suppressed (unpublished results). Flavonoids such as luteolin, quercetin, fisetin, and myricetin
are best-known for their antioxidant and metal chelation activities [53,54]. Quercetin, together with
(−) epigallocatechin-3-gallate, was found previously as a compound which has strong activity to
restrain α-synuclein toxicity in a yeast model system of PD [23]. From the SAR analysis, the authors
concluded that these compounds act by virtue of antioxidant and metal chelating properties; these
conclusions were also supported by the observation that iron salt negatively affected this model system.
Our SAR analysis similarly showed that the suppressor activity of flavonoid compounds correlated
with the same structural requirements as for their iron-binding and antioxidant properties. However,
anthocyanins and anthocyanidins, both very potent antioxidants from another structural group, which
were present among the compounds in the in-house library of natural compounds, as well as several
other antioxidants that we tested, such as trolox, kaempferol, and catechin [54], were unable to restore
the growth of vps13∆ cells in the presence of SDS. Altogether, the data suggest that the protective
action of flavonoids is rather not related to antioxidant action but, instead, depends on mechanisms
linked to their metal-binding properties.
In contrast to the results obtained by testing flavonoids using the yeast model of PD [23],
the addition of iron salts showed positive effects in our model system, suggesting that increased cellular
levels of iron can help to overcome disturbances caused by Vps13 deficiency. In support of this idea,
the iron siderophore enterobactin, which transports iron into cells, was also a very potent suppressor
of vps13∆. Moreover, in our genetic screen, the FET4 gene, encoding a low-affinity iron transporter,
was found as a multicopy suppressor of the vps13∆ growth defect, showing again that increased iron
transport into the cell is helpful in this condition. Interestingly, luteolin restored the growth of vps13
cells regardless of the presence of multiple copies of FET4; thus, the effect of these two factors was not
additive, suggesting that they act on the same process. Possible mechanisms of flavonoids and iron
action involve binding to specific proteins, affecting metabolic or signaling pathways, or changing
gene expression to induce a protective response in cells against SDS stress [63,64].
Increased sensitivity to SDS suggests the defective structure of cellular membranes in the
vps13 mutant. Membranes are composed of a complex mixture of lipids, including sphingolipids.
The composition of membrane lipids changes along with the secretory pathway in S. cerevisiae:
Sphingolipids are generated in the ER and Golgi, then delivered to the plasma membrane where they
are most abundant [65] and play a significant role in responding to various stresses, both as building
components and as signaling molecules. By using the yeast genetic approach, we have demonstrated
the link of Vps13 and luteolin with a sphingolipid pathway. The ipt1∆ and csg2∆ mutations causing
defects in complex sphingolipid biosynthesis are suppressed by luteolin and iron salt, and negatively
interact with vps13∆. One may find indirect connections between Vps13 and sphingolipids through the
analysis of previously published data. Noteworthy, vps13/soi1 mutants were originally selected in the
screen for suppressors of kex2 mutation disturbing Kex2 protease activity in late Golgi [66] and it was
further documented that vps13 mutation affects retrograde traffic of proteins (such as Vps10 receptor)
between endosome and late Golgi [67]. As defects in retrograde vesicular transport between endosomes
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and Golgi apparatus result in disturbances in sphingolipid biosynthesis [68], this led to the assumption
that the vps13 mutant may have disturbed sphingolipid biosynthesis as well. Moreover, the first step
of complex sphingolipid synthesis—the conversion of ceramide to IPC—is essential for the viability
of the cell and its regulation involves processing by Kex2 protease [69]. As it has been documented
that vps13 affects wild-type Kex2 cycling between trans Golgi and endosomes [67], vps13∆ mutation
may negatively affect IPC levels. In addition, examination of reporters for different lipids showed that
prospore membranes in vps13 cells have reduced levels of phosphatidylinositol-4-phosphate (PI(4)P),
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), and phosphatidic acid [70]. Reduction of the latter
two lipids could account for an effect on PI(4)P levels [71,72] which, in turn, may also negatively affect
IPC levels [73] in vps13∆ cells as well. Sphingolipid homeostasis is regulated by complicated sensing
and feedback mechanisms, which involve signaling pathways regulating the L-serine:palmitoyl-CoA
acyltransferase (SPT), the first enzyme of the sphingolipid biosynthesis pathway [74,75], and changed
response of cells to myriocin—the inhibitor of this enzyme—can indicate disturbances in sphingolipid
biosynthesis [68,71,76]. Possible defects in sphingolipids in vps13 cells which are also resistant to
myriocin [68] require further study.
Sphingolipid synthesis is also linked to iron, as high iron levels cause an increase of total
sphingolipid precursors, such as long-chain bases (dihydrosphingosine and phytosphingosine) and
their phosphate derivatives, where decreasing these levels by myriocin treatment increases yeast
tolerance to high iron. Sphingolipids play a signaling role in iron response, as the loss of Pkh1 and Ypk1
kinases [64], which respond to and regulate sphingolipid levels, increases iron tolerance in yeast [77].
We did not observe the hallmark of iron deficiency in vps13∆ mutant cells and no iron deficiency
was found in the vps13-D716H mutant by others [78]; however, increased iron levels in response to
SDS might be helpful in stress defense. Interestingly, sphingolipid homeostasis is also a target of
luteolin in human cancer cells [79]. Thus, the addition of luteolin or iron salts to the SDS-containing
medium may correct defects of Vps13 deficiency and promote growth by affecting the synthesis of
sphingolipid precursors.
Dysregulation of sphingolipid metabolism is involved in a great deal of neurodegenerative
disorders, manifesting in neurological symptoms as sphingolipids are highly enriched in the nervous
system, where they play important regulatory roles. For example, mutations in genes encoding
sub-units of SPT have been shown to cause sensory and autonomic neuropathy type 1 (HSAN1) [80].
Defects in retrograde vesicular transport have been shown to cause disturbances in sphingolipid
biosynthesis and result in the human neurodegenerative disease cerebello-cerebral atrophy type 2
(PCCA2) [68,81]. Sphingolipid metabolism is also perturbed in AD, PD, and HD. With the emerging
role of ceramide and sphingosine-1-phosphate (S1P) as cell-signaling hubs in the pathophysiology
of several neurodegenerative diseases, unified therapeutic approaches are possible. It is not known
if, in yeast or human cells devoid of VPS13 proteins, the sphingolipid homeostasis is disturbed,
which remains to be analyzed. However, deficiency of Vps13A negatively affects the PI(4)P pool, which
affects the synthesis of complex sphingolipids in mammalian cells [82]. Thus, it is possible that VPS13
negatively affects sphingolipid homeostasis and the drugs selected here, tolcapone and flavonoids,
alleviated this defect.
5. Conclusions
The screening of drug candidates using yeast models of neurodegenerative diseases has already
proved efficient to isolate compounds that were later shown to be active in patient-derived cells.
This study revealed that tolcapone and several natural flavonoids, including luteolin, exert positive
effects on a vps13∆ yeast model of VPS13-dependent rare neurodegenerative diseases. These compounds
may represent candidates for drug repurposing and dietary supplementation as a potential strategy to
improve the existing symptomatic treatments of these diseases. Characterization of the mechanism of
luteolin action revealed iron homeostasis and sphingolipid biosynthesis as possible targets. Our study
also indicates that further research on sphingolipids in cells devoid of the Vps13 protein is critical
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to better understand the pathogenesis of VPS13-dependent rare neurodegenerative diseases and to
develop effective therapeutic strategies.
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